Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04604509 · ClinicalTrials.gov registry record · Phase 4

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

A Phase 4 study of Cigarette Smoking-Related Carcinoma, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 4
Development phase
2,010
Enrollment target
1
Study location

NCT04604509: Recruiting Phase 4 study of Cigarette Smoking-Related Carcinoma, sponsored by M.D. Anderson Cancer Center.

NCT04604509 is a Phase 4 study of Cigarette Smoking-Related Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 2,010 participants, above the 372-participant average among 21 other Cigarette Smoking-Related Carcinoma trials with a reported enrollment target (440% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04604509, a Phase 4 study of Cigarette Smoking-Related Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 4
Development phase
2,010 participants
Enrollment target
1
Study location

Study Summary

This phase IV trial investigates how to personalize treatments (such as medications and/or counseling) for quitting smoking based on the unique character traits of participants. Nicotine replacement therapy, counseling, and/or drugs such as varenicline and bupropion may help participants quit smoking or change smoking behavior. This trial may also help doctors individualize smoking cessation treatment for participants who do not quit smoking after the first course of treatment.

Primary Outcome

Will use Bayesian statistical methods to estimate these effects and their accompanying posterior probabilities.

Interventions

  • OTHER Questionnaire Administration
  • DRUG Varenicline
  • DRUG Bupropion Hydrochloride Controlled-release
  • DRUG Nicotine Replacement
  • OTHER Tobacco Cessation Counseling

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 2,010 participants
Start Date 2020-08-04
Est. Completion 2028-12-31
Phase Phase 4
M.D. Anderson Cancer Center

2,692 total trials

What NCT04604509 shows while recruiting

NCT04604509 is an interventional study that assigns participants to a tested intervention. Its 2,010 participants enrollment target places it among the larger protocols in the corpus, above the 372-participant average among 21 other Cigarette Smoking-Related Carcinoma trials with a reported enrollment target (440% higher).

The record links to 1 condition, with Cigarette Smoking-Related Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Questionnaire Administration is the first listed.

NCT04604509 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT04604509 about?

NCT04604509 is a clinical study titled "Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial". This phase IV trial investigates how to personalize treatments (such as medications and/or counseling) for quitting smoking based on the unique character traits of participants. Nicotine replacement therapy, counseling, and/or drugs such as varenicline and bupropion may help participants quit smokin...

What is the current status of trial NCT04604509?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 2,010 participants. The study started on 2020-08-04. Estimated completion is 2028-12-31.

What conditions does trial NCT04604509 study?

This clinical trial studies the following conditions: Cigarette Smoking-Related Carcinoma.

What interventions are being tested in trial NCT04604509?

The interventions under investigation include: Questionnaire Administration (OTHER), Varenicline (DRUG), Bupropion Hydrochloride Controlled-release (DRUG), Nicotine Replacement (DRUG), Tobacco Cessation Counseling (OTHER).

Who is sponsoring clinical trial NCT04604509?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04604509 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cigarette Smoking-Related Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04604509's enrollment target sits among peer trials

2,010 1st of 21 higher than 21 of 21 other Cigarette Smoking-Related Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cigarette Smoking-Related Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04100564 · 2,009 participants · NA

    LITES Task Order 0005 Prehospital Airway Control Trial (PACT)

  • NCT05059444 · 2,020 participants

    ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • NCT00001465 · 2,000 participants

    Study of the Disease Process of Lymphangioleiomyomatosis

  • NCT00001595 · 2,000 participants

    An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04604509, the US trial registry maintained by the National Library of Medicine. NCT04604509 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.